CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company that develops and sells therapeutic products for life-threatening diseases and conditions. The company's main focus has been the commercialization of DefenCath® (taurolidine and heparin) in the U.S., which it launched in 2024 for use in hemodialysis. On August 29, 2025, CorMedix Inc. acquired Melinta Therapeutics, LLC, expanding its team and commercial platform. This acquisition increased the company's commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products: REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection ("MINOCIN IV"), VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), and BAXDELA® (delafloxacin). The acquisition also included TOPROL-XL® (metoprolol succinate), a cardiovascular product. The Melinta Portfolio supports a multi-channel strategy for delivering anti-infectives for serious gram-positive, gram-negative, and fungal infections within hospitals and the hospital ecosystem, including emergency departments, outpatient clinics, and home infusion care. The company's corporate strategy focuses on maximizing the value of its current portfolio, with promotional efforts concentrated on DefenCath, REZZAYO, MINOCIN IV, and VABOMERE.